Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Aligos Therapeutics, maintaining a price target of $50. The rating is supported by the company's strategic execution and promising pipeline, particularly its lead program, pevifoscorvir sodium, currently in Phase 2 trials for chronic hepatitis B. The drug shows potential for significant revenue, estimated at over $1.8 billion annually. Aligos is also exploring its ALG-055009 program, enhancing its strategic positioning in the market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments